Assembly Biosciences (ASMB) Long-Term Investments (2015 - 2022)

Assembly Biosciences' Long-Term Investments history runs 6 years deep, the most recent figure standing at $11.7 million for Q4 2022.

• On a quarterly basis, Long-Term Investments fell 58.02% year-over-year to $11.7 million in Q4 2022; TTM through Dec 2022 was $11.7 million, a 58.02% decrease from a year earlier, with the FY2022 full-year figure at $11.7 million, down 58.02% from the prior year.
• Long-Term Investments declined to $11.7 million in Q4 2022 per ASMB's latest filing, from $11.9 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $28.0 million in Q4 2021 and bottomed at $2.2 million in Q2 2018.
• The 3-year median for Long-Term Investments is $11.8 million (2022), against an average of $14.4 million.
• Across the five-year window, Long-Term Investments decreased 26.75% in 2018 and plunged 58.02% in 2022, its largest moves.
• Year by year, Long-Term Investments stood at $2.2 million in 2018, then surged by 1169.09% to $28.0 million in 2021, then plunged by 58.02% to $11.7 million in 2022.
• Per Business Quant, the three latest ASMB Long-Term Investments figures stand at $11.7 million (Q4 2022), $11.9 million (Q2 2022), and $23.5 million (Q1 2022).